Junhe Q. Li - Publications

Real-World Study of anti-PD-1 Combined with Regorafenib and Raltitrexed as Third-Line Therapy in Colorectal Cancer.

Journal: Journal of gastrointestinal cancer

Published: December 24, 2025

CircSLC4A7 in resistant-cells-derived exosomes promotes docetaxel resistance via the miR-1205/MAPT axis in prostate cancer.

Journal: IUBMB life

Published: July 08, 2024

A novel biomarker GATM suppresses proliferation and malignancy of cholangiocarcinoma cells by modulating the JNK/c-Jun signalling pathways.

Journal: Heliyon

Published: May 01, 2024

Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 28, 2024

Real-world retrospective study of anti-PD-1 antibody in combination with chemotherapy as a neoadjuvant treatment strategy for locally advanced resectable esophageal squamous cell carcinoma.

Journal: Journal of thoracic disease

Published: January 29, 2024

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: October 17, 2023

A case report of two instances of colorectal hepatoid adenocarcinoma, accompanied by a comprehensive literature review.

Journal: Journal of cancer research and clinical oncology

Published: October 02, 2023

Research advances on pharmacological interventions for hypertrophic scar

Journal: Zhonghua shao shang yu chuang mian xiu fu za zhi

Published: January 03, 2023

Clinicopathological characteristics, survival outcome and prognostic factors of very young gastric cancer.

Journal: Clinical and experimental medicine

Published: December 24, 2021

The microRNA-381(miR-381)/Spindlin1(SPIN1) axis contributes to cell proliferation and invasion of colorectal cancer cells by regulating the Wnt/β-catenin pathway.

Journal: Bioengineered

Published: November 10, 2021

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.

Journal: Cancer cell

Published: November 02, 2021

USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer.

Journal: Oncogene

Published: September 12, 2021